A TPO receptor agonist, ALXN4100TPO, mitigates radiation-induced lethality and stimulates hematopoiesis in CD2F1 mice

Radiation Research

Volumn 175, Issue 6, 2011, Pages 746-758

  Satyamitra, Merriline ^a   Lombardini, Eric ^a   Graves III, John ^a   Mullaney, Conor ^a   Ney, Patrick ^a   Hunter, Jeffrey ^b   Johnson, Krista ^b   Tamburini, Paul ^b   Wang, Yi ^b   Springhorn, Jeremy P ^b   Srinivasan, Venkataraman ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4100 TPO; CYTOKINE RECEPTOR AGONIST; MONOCLONAL ANTIBODY; RADIOPROTECTIVE AGENT; RECOMBINANT THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL MATURATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; HEMATOPOIESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION PROTECTION; RADIATION SICKNESS; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION; WHOLE BODY RADIATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIESIS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTROPHILS; RADIATION-PROTECTIVE AGENTS; RECEPTORS, THROMBOPOIETIN; THROMBOPOIESIS; THROMBOPOIETIN;

MUS;

EID: 79957586529     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2462.1     Document Type: Article

References (49)

1. van Bekkum DW. Radiation sensitivity of the hemopoietic stem cell. Radiat Res 1991; 128(Suppl):S4-8.
2. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004; 162:711-28. (Pubitemid 39552901)
3. Coleman CN, Stone HB, Moulder JE, Pellmar TC. Medicine. Modulation of radiation injury. Science 2004; 304:693-4.
4. Moulder JE. Post-irradiation approaches to treatment of radiation injuries in the context of radiological terrorism and radiation accidents: a review. Int J Radiat Biol 2004; 80:3-10. (Pubitemid 38365707)
5. Weiss JF, Landauer MR. History and development of radiationprotective agents. Int J Radiat Biol 2009; 85:539-73.
6. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276:1696-9. (Pubitemid 27421976)
7. Akahori H, Shibuya K, Obuchi M, Nishizawa Y, Tsuji A, Kabaya K, et al. Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br J Haematol 1996; 94:722-8. (Pubitemid 26308910)
8. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest 1996; 97:2145-51.
9. Grossmann A, Lenox J, Ren HP, Humes JM, Forstrom JW, Kaushansky K, et al. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice. Exp Hematol 1996; 24:1238-46. (Pubitemid 26276587)
10. Hokom MM, Lacey D, Kinstler OB, Choi E, Kaufman S, Faust J, et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86:4486-92.
11. Kaushansky K, Broudy VC, Grossmann A, Humes J, Lin N, Ren HP, et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995; 96:1683-7.
12. Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel KH, Broudy VC. Thrombopoietin expands erythroid, granulocytemacrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol 1996; 24:265-9. (Pubitemid 26093895)
13. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457-69. (Pubitemid 35303910)
14. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000; 37(Suppl 4):3-10. (Pubitemid 30332058)
15. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607-16. (Pubitemid 46827750)
16. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-8.
17. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 2000; 37(Suppl 4), :28-34. (Pubitemid 30332061)
18. Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S347-56.
19. de Serres M, Yeager RL, Dillberger JE, Lalonde G, Gardner GH, Rubens CA, et al. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. Stem Cells 1999; 17:316-26.
20. Frederickson S, Renshaw MW, Lin B, Smith LM, Calveley P, Springhorn JP, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA 2006; 103:14307-12. (Pubitemid 44484746)
21. Wild MA, Kumor K, Nolan MJ, Lockman H, Bowdish KS. A human antibody against anthrax protective antigen protects rabbits from lethal infection with aerosolized spores. Hum Antibodies 2007; 16:99-105. (Pubitemid 351359899)
22. Bowdish KS, Frederickson S, Wild MA, Maruyama T, Nolan MJ, inventors; Immunotherapeutics for biodefense. USA patent US2004/0009178A1. January, 2004.
23. Wild MA, Xin H, Maruyama T, Nolan MJ, Calveley PM, Malone JD, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003; 21:1305-6. (Pubitemid 37356614)
24. Bebbington CR. Expression of antibody genes in non-lymphoid mammalian cells. In Methods: A companion to methods in enzymology 2. London/New York: Academic Press; 1991.
25. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1319-39.
26. Neta R. Modulation of radiation damage by cytokines. Stem Cells. 1997; 15 Suppl 2:87-94. (Pubitemid 27494842)
27. Herodin F, Roy L, Grenier N, Delaunay C, Bauge S, Vaurijoux A, et al. Antiapoptotic cytokines in combination with pegfilgrastim soon after irradiation mitigates myelosuppression in nonhuman primates exposed to high irradiation dose. Exp Hematol 2007; 35:1172-81. (Pubitemid 47088776)
28. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, et al. Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140:1037-51.
29. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161-71.
30. Kaushansky K. The mpl ligand: molecular and cellular biology of the critical regulator of megakaryocyte development. Stem Cells 1994; 12 Suppl 1:91-6; discussion 6-7.
31. Mouthon MA, Van der Meeren A, Vandamme M, Squiban C, Gaugler MH. Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: importance of time scheduling. Can J Physiol Pharmacol 2002; 80:717-21. (Pubitemid 35430410)
32. Mouthon MA, Van der Meeren A, Gaugler MH, Visser TP, Squiban C, Gourmelon P, et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys 1999; 43:867-75. (Pubitemid 29152660)
33. Whitnall MH, Villa V, Seed TM, Benjack J, Miner V, Lewbart ML, et al. Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice. Immunopharmacol Immunotoxicol 2005; 27:15-32. (Pubitemid 40389447)
34. Kim K, Pollard JM, Norris AJ, McDonald JT, Sun Y, Micewicz E, et al. High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res 2009; 15:7238-45.
35. Herodin F, Mayol JF, Mourcin F, Drouet M. Which place for stem cell therapy in the treatment of acute radiation syndrome? Folia Histochem Cytobiol 2005; 43:223-7. (Pubitemid 41582143)
36. Weiss JF. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect 1997; 105 Suppl 6:1473-8. (Pubitemid 28050944)
37. Ghosh SP, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao TC, et al. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol 2009; 85:598-606.
38. Arai F, Hirao A, Suda T. Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 2005; 82: 371-6. (Pubitemid 46638683)
39. Herodin F, Bourin P, Mayol J-F, Lataillade J-J, Drouet M. Short-term injection of antiapoptotic cytokine combinations soon after lethal (gamma)-irradiation promotes survival. Blood 2003; 101:2609-16. (Pubitemid 36857620)
40. MacVittie TJ, Farese AM. Cytokine-based treatment of radiation injury: potential benefits after low-level radiation exposure. Mil Med 2002; 167(Suppl):68-70. (Pubitemid 34174189)
41. Patchen ML, MacVittie TJ, Solberg BD, D'Alesandro MM, Brook I. Radioprotection by polysaccharides alone and in combination with aminothiols. Adv Space Res 1992; 12:233-48.
42. Tanikawa S, Nose M, Aoki Y, Tsuneoka K, Shikita M, Nara N. Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 1990; 76:445-9. (Pubitemid 20251808)
43. Van der Meeren A, Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P. Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin. Radiat Res. 2002; 157:642-9. (Pubitemid 34569131)
44. Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, et al. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. Int J Immunopharmacol 2000; 22:1-14. (Pubitemid 30102256)
45. Seed TM, Cullen SM, Kaspar LV, Tolle DV, Fritz TE. Hemopathologic consequences of protracted gamma irradiation: alterations in granulocyte reserves and granutocyte mobilization. Blood 1980; 56:42-51. (Pubitemid 10086956)
46. Satyamitra M, Lombardini E, Mullaney C, Graves III J, Ney P, Srinivasan V. ALXN4100TPO mitigates radiation-induced bone marrow injury by promoting multilineage hematopoietic recovery. Blood. Forthcoming 2011.
47. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92:4-10. (Pubitemid 28303168)
48. Young JC, Bruno E, Luens KM, Wu S, Backer M, Murray LJ. Thrombopoietin stimulates megakaryocytopoiesis, myelopoiesis, and expansion of CD34z progenitor cells from single CD34zThy-1zLin2 primitive progenitor cells. Blood 1996; 88:1619-31. (Pubitemid 26307056)
49. Kobayashi M, Laver JH, Lyman SD, Kato T, Miyazaki H, Ogawa M. Thrombopoietin, steel factor and the ligand for flt3/flk2 interact to stimulate the proliferation of human hematopoietic progenitors in culture. Int J Hematol 1997; 66:423-34. (Pubitemid 28137230)